KindlyMD (NASDAQ:NAKA) CEO Acquires $25,180.16 in Stock

Posted by Brian Himes on Aug 23rd, 2026

KindlyMD, Inc. (NASDAQ:NAKA – Get Free Report) CEO David Bailey purchased 4,918 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were purchased at an average cost of $5.12 per share, with a total value of $25,180.16. Following the completion of the purchase, the chief executive officer owned 3,180,394 shares in the company, valued at $16,283,617.28. This trade represents a 0.15% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

KindlyMD Price Performance

KindlyMD stock opened at $7.06 on Friday. KindlyMD, Inc. has a 1-year low of $3.33 and a 1-year high of $422.40. The firm has a market capitalization of $126.37 million, a P/E ratio of -0.20 and a beta of 15.95. The company’s 50-day moving average is $4.54 and its 200 day moving average is $7.24.

KindlyMD (NASDAQ:NAKA – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($6.65) earnings per share (EPS) for the quarter. The firm had revenue of $35.87 million during the quarter. KindlyMD had a negative return on equity of 63.45% and a negative net margin of 1,067.93%. Research analysts anticipate that KindlyMD, Inc. will post -11.31 earnings per share for the current fiscal year.

KindlyMD News Summary

Here are the key news stories impacting KindlyMD this week:

Positive Sentiment: CEO David F. Bailey purchased 4,918 shares at an average price of $5.12, investing approximately $25,180. The transaction raised his direct ownership to 3.18 million shares, which may reassure investors about management’s confidence in KindlyMD’s long-term outlook. CEO stock purchase article
Neutral Sentiment: Maxim Group improved its EPS forecasts for the fourth quarter of 2026 and the first two quarters of 2027, projecting smaller losses of $0.48, $0.76 and $0.74 per share, respectively. These revisions are modestly encouraging but still indicate that KindlyMD is not expected to reach profitability in the near term. KindlyMD analyst estimates
Negative Sentiment: Maxim lowered its third-quarter 2026 EPS forecast to a $0.49 loss from a $0.43 loss, cut its fourth-quarter 2027 estimate to a $0.43 loss from a $0.41 loss, and reduced its full-year 2027 forecast to a $2.12 loss from a $1.44 loss. The full-year downgrade points to weaker expected profitability and offsets some of the improved quarterly estimates.
Negative Sentiment: KindlyMD’s latest reported quarter showed a $6.65-per-share loss on $35.87 million of revenue, alongside a deeply negative net margin. The company is expected to post a loss of approximately $11.31 per share for the current year, while analyst coverage remains mixed, including sell ratings. KindlyMD financial and insider trading data

Analyst Ratings Changes

A number of research firms recently issued reports on NAKA. Wall Street Zen upgraded KindlyMD to a “sell” rating in a report on Saturday, May 23rd. TD Cowen increased their target price on KindlyMD from $1.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KindlyMD in a research report on Friday, August 7th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $22.33.

Check Out Our Latest Stock Analysis on KindlyMD

Hedge Funds Weigh In On KindlyMD

A number of institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its stake in shares of KindlyMD by 76.2% during the second quarter. Geode Capital Management LLC now owns 19,394 shares of the company’s stock valued at $484,000 after acquiring an additional 8,386 shares in the last quarter. Osaic Holdings Inc. bought a new position in KindlyMD in the second quarter worth approximately $215,000. Tower Research Capital LLC TRC grew its stake in KindlyMD by 1,638.4% in the third quarter. Tower Research Capital LLC TRC now owns 33,152 shares of the company’s stock worth $827,000 after purchasing an additional 31,245 shares in the last quarter. Victory Capital Management Inc. purchased a new position in KindlyMD during the 3rd quarter worth $1,007,000. Finally, Vident Advisory LLC purchased a new position in KindlyMD during the 3rd quarter worth $2,092,000.

KindlyMD Company Profile

(Get Free Report)

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.